Clinical Trial Update: Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update for Apokyn aimed at improving morning akinesia in Parkinson's disease; status completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Apokyn (apomorphine)

Snippet

Sponsor: MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | Conditions: Parkinson's Disease, Motor Symptoms | Phase 4 | Status: COMPLETED | Results posted: 2015-09-07